![]() ![]() Awareness of CBS among ophthalmologist is essential. ![]() The Charles Bonnet syndrome (CBS) is characterised by complex visual hallucinations in elderly patients in the setting of significant visual impairment without any psychiatric symptoms. Visual hallucinations disappeared within 10 days after discontinuing the drug. Neurologic and psychiatric examination was normal. GarcÃa-Catalán, M R Arriola-Villalobos, P Santos-Bueso, E Gil-de-Bernabé, J DÃaz-Valle, D BenÃtez-del-Castillo, J M GarcÃa-Sánchez, JĪn 81-year-old woman with age-related macular degeneration and pseudoexfoliative glaucoma developed visual hallucinations (faces, flowers and frames) shortly after beginning brimonidine drops. ![]() Brimonidine and brimonidine-timolol are well tolerated in normal horses but do not decrease IOP. Horses with normal eyes may not be as sensitive to the IOP-lowering effects of treatment as horses with glaucoma. However, IOP differences were of ≤1 mmHg and thus not clinically important. Average IOP in normal equine eyes treated with brimonidine (25.6 mmHg) was statistically higher than in eyes treated with brimonidine-timolol (24.6 mmHg) or BSS (24.5 mmHg). There were no adverse effects and no significant changes in pupil size in normal equine eyes treated with brimonidine or brimonidine-timolol. One eye of each horse was treated with brimonidine or brimonidine-timolol and the opposite eye was treated with balanced salt solution (BSS). Pupil size and conjunctival hyperaemia were assessed twice per day and IOP was measured three times per day using rebound tonometry in both eyes of 16 normal horses throughout two 10-day study periods ( brimonidine and brimonidine-timolol) separated by an 18-day washout period. Four horses were randomly assigned to each of four combinations of treated eye (right or left) and drug order within the two 10-day study phases ( brimonidine first or brimonidine-timolol first). A balanced crossover design with 16 horses receiving one of two treatments, brimonidine and brimonidine-timolol, during each of two 10-day study phases, was used. To evaluate the efficacy and safety of brimonidine in lowering intraocular pressure (IOP), alone and in conjunction with timolol, as a treatment for equine glaucoma by comparing IOP in normal equine eyes treated with brimonidine and brimonidine-timolol, respectively, with IOP in control eyes. It has not been evaluated in normal or glaucomatous equine eyes. Von Zup, M Lassaline, M Kass, P H Miller, P E Thomasy, S Mīrimonidine is an α 2 -adrenergic agonist that decreases aqueous humour production and may increase uveoscleral outflow. Effects of 0.2% brimonidine and 0.2% brimonidine-0.5% timolol on intraocular pressure and pupil size in normal equine eyes. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |